3 Results for "

bone marrow abnormalities

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "bone marrow abnormalities" in MCE Product Catalog:

Cat. No.: HY-W088068
CAS No.: 68988-92-1
Wright's stain is a composite cell stain that mainly binds to intracellular nucleic acids, proteins and other components through thiazine dyes (such as methylene blue) and eosin. Wright's stain is pH-dependent (optimal pH 6.4-6.7) and achieves cell morphology resolution by differentially staining the cytoplasm and nucleus. Under alkaline conditions, thiazine dyes bind to nucleic acids to form purple, and acidic eosin binds to cytoplasmic proteins to form red, which can form contrasting cell morphological features. Wright's stain can clearly display the fine structures of blood cells and bone marrow cells (such as nuclear chromatin and granules) and quickly evaluate cell morphological abnormalities .
loading...
    loading...
Cat. No.: HY-L171
4,388 compounds

Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs.

MCE designs a unique collection of 4,388 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

Cat. No.: HY-L079
4,333 compounds

Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.

Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.

MCE offers a unique collection of 4,333 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.